Yes, treatment can significantly slow the progression of Multiple Sclerosis. In modern clinical practice, the goal has moved beyond just managing symptoms to actively changing the trajectory of the disease. While there is currently no cure, evidence confirms that early and consistent use of disease modifying therapies (DMTs) can reduce the accumulation of physical and cognitive disability by years. These treatments work by suppressing the inflammatory attacks that lead to nerve damage and, crucially, by protecting against the slow loss of brain volume that occurs even between visible relapses. By starting high efficacy treatment early, many individuals are now able to maintain their independence and functional abilities for much longer than was possible in previous decades.
What we will discuss in this article
- The long term impact of early vs delayed treatment
- How DMTs protect brain volume and neurological reserve
- Slowing progression in Primary and Secondary Progressive MS
- The modern standard: High efficacy therapies as a first line
- Breakthroughs in BTK inhibitors for non relapsing progression
- Measuring success through NEDA (No Evidence of Disease Activity)
- Emergency guidance for rapid disability worsening
The window of opportunity: Early intervention
One of the most important findings in neurology is the critical importance of treating Multiple Sclerosis as soon as a diagnosis is confirmed.
Clinical studies have identified a window of opportunity in the first few years of the disease. During this time, the nervous system has a higher capacity to compensate for damage. Starting high efficacy treatment during this phase can delay the need for walking aids or the transition to secondary progressive MS by a decade or more. Waiting for the disease to worsen before escalating treatment, a strategy known as escalation therapy, is increasingly being replaced by a top down approach where the most potent drugs are used first to freeze the disease in its tracks.
Protecting brain volume
Beyond stopping relapses, modern treatments are now proven to slow down the rate of brain atrophy (brain shrinkage).
In everyone, the brain naturally shrinks slightly with age, but this process is accelerated in Multiple Sclerosis. This loss of brain tissue is directly linked to long term cognitive decline and physical disability. Large scale analyses have confirmed that high efficacy DMTs significantly reduce this volume loss, with some medications cutting the rate of shrinkage by nearly 50 percent. By preserving more brain tissue, these treatments help maintain neurological reserve, allowing the brain to better handle the effects of the disease over time.
Slowing progression in Progressive MS
For many years, treatment for progressive forms of the disease was limited, but recent years have seen major breakthroughs in this area.
For Primary Progressive MS (PPMS) and active Secondary Progressive MS (SPMS), specific treatments are used to slow down the accumulation of disability. A major milestone has been the success of a new class of drugs called BTK inhibitors. These oral medications can cross the blood brain barrier to target the chronic, smouldering inflammation that drives disability even when there are no active relapses. These drugs have shown a significant delay in disability progression for non relapsing progressive patients, providing the first real hope for those in the later stages of the disease.
The role of biosimilars in expanding access
New clinical guidelines have recommended the use of natalizumab biosimilars to expand access to high efficacy care.
By introducing more affordable versions of highly effective drugs, health systems are now able to offer these potent treatments to a wider range of patients earlier in their disease course. This change is vital because it removes the financial and administrative barriers that previously forced many people to stay on less effective treatments while their disease slowly progressed. Increased access to these biological therapies is a key reason why the overall rate of disability accumulation in the MS population is beginning to drop.
Emergency guidance
While most progression is slow and steady, any rapid change in your physical or cognitive abilities requires immediate clinical investigation.
Seek immediate medical help if you experience a rapid loss of movement or vision over a few hours, as this may indicate a severe acute relapse or a separate neurological emergency that requires high dose intervention to prevent permanent damage.
Seek urgent medical advice if you notice:
- A sudden inability to walk that was not present 24 hours ago
- New and total loss of bladder or bowel control
- Signs of a severe systemic infection while on high efficacy DMTs
- A sudden, severe change in your ability to swallow or speak clearly
- Rapidly worsening memory or confusion that interferes with your safety
To summarise
Treatment is highly effective at slowing the progression of Multiple Sclerosis. By utilising high efficacy disease modifying therapies early in the disease course, clinicians can significantly reduce the risk of long term disability and protect vital brain volume. While the challenges of progressive MS remain, the emergence of brain penetrant BTK inhibitors and expanded access to biological therapies through biosimilars are providing new ways to stall the disease. The goal of modern MS care is no longer just to wait and see, but to proactively protect the nervous system to ensure a higher quality of life for years to come.
Can treatment stop progression entirely?
For some people, treatment can lead to NEDA (No Evidence of Disease Activity), where the disease appears to stop for many years. However, some very slow progression can still occur beneath the surface, which is why regular monitoring is essential.
Does treatment work for everyone?
While treatments are effective for the vast majority, the degree of benefit varies. Personalised medicine helps doctors find the specific drug that works best for your unique biology.
Is it too late to start treatment if I already have disability?
No. Treatment can still be effective at slowing down further progression and preventing new relapses, helping you maintain the function you currently have.
How do I know if my treatment is working?
Your medical team will use annual MRI scans, walking tests, and cognitive assessments to ensure the disease is stable. If new activity is found, they may suggest switching to a more potent therapy.
Do biosimilars work as well as the original drugs?
Yes. Biosimilars go through rigorous testing to prove they provide the exact same clinical outcomes and safety as the original brand name treatments.
Can lifestyle changes help slow progression too?
Yes. Staying active, managing stress, and maintaining healthy Vitamin D levels are important supportive measures that work alongside your medical treatment to protect your brain.
What is PIRA?
PIRA stands for Progression Independent of Relapse Activity. It refers to the slow worsening of symptoms that happens without a clear flare up. Modern DMTs are increasingly focused on stopping this specific type of progression.
Authority Snapshot
This article was reviewed by Dr. Stefan Petrov, a UK trained physician with an MBBS and extensive experience in general medicine, intensive care, and emergency medicine. Dr. Petrov has worked in various clinical environments, including surgery and ophthalmology, and is a strong advocate for patient education. He is dedicated to providing up to date, evidence based health information to help patients understand how modern therapies can protect their long term neurological health.
